• 𝐍𝐞𝐮𝐫𝐨𝐦𝐲𝐞𝐥𝐢𝐭𝐢𝐬 𝐎𝐩𝐭𝐢𝐜𝐚 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐨 𝟑.𝟔𝟎% 𝐂𝐀𝐆𝐑 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝟐𝟎𝟑𝟎
    According to Regional Research Reports," the Global Neuromyelitis Optica Drug Market is projected to reach USD 120 million by 2030 from USD 53 million in 2021, growing at a CAGR of 3.60% from 2022 to 2030.

    Regional Research Reports offers comprehensive insights into the global Neuromyelitis Optica Drug Market, facilitating an in-depth understanding of its dynamics. By conducting thorough research and employing robust data analysis techniques, this study aims to provide valuable insights into the current landscape of business, as well as the challenges and opportunities that shape the market under consideration. Considering the shifting dynamics of the environment, it is crucial to prioritize decision-making that is well-informed. The report provides individuals with the necessary knowledge and techniques to make informed and effective business decisions.
    Request Sample Copy of this Report: https://www.regionalresearchreports.com/request-sample/neuromyelitis-optica-drug-market/HC-1358?utm_source=Free&utm_medium=Harsh+26+dec

    Global Neuromyelitis Optica Drug Market Segmentation

    Key Market Segments:
    Immunosuppressants:

    Azathioprine
    Mycophenolate mofetil
    Rituximab
    Methotrexate
    Corticosteroids:

    Prednisone
    Methylprednisolone
    Plasma Exchange (PLEX):

    Used for acute attacks to remove antibodies from the blood.
    Monoclonal Antibodies:

    Eculizumab
    Other Therapies:

    Aquaporin-4 (AQP4) antibody-targeted therapies
    Inebilizumab
    Global Neuromyelitis Optica Drug Market Competitive: Key Players
    The report offers an exhaustive analysis of the key players operating in the Neuromyelitis Optica Drug Market( on a global scale. These competitors have implemented various strategies, including the introduction of new products, partnerships, growth, joint ventures, and agreements, among others, in order to expand their market presence and sustain their dominant positions in distinct regions.

    In terms of revenue, the global two largest companies occupied for a share nearly % in 2023. The main players in the global market include –

    Genentech/Roche:

    Developed Satralizumab (Enspryng), a monoclonal antibody for NMO treatment.
    Viela Bio:

    Developed Inebilizumab (Uplizna), a B-cell-depleting antibody for the treatment of NMO.
    Alexion Pharmaceuticals:

    Developed Eculizumab (Soliris), a complement inhibitor used in the treatment of NMO.
    Horizon Therapeutics:

    Involved in the development of Ravulizumab, another complement inhibitor, for NMO treatment.
    Chugai Pharmaceutical (a member of the Roche Group):

    Collaborated on the development of Satralizumab.
    MedImmune/AstraZeneca:

    Involved in the development of Inebilizumab.
    Teva Pharmaceutical Industries:

    Manufacturer of glatiramer acetate (Copaxone), which may be used off-label in some cases.
    Mitsubishi Tanabe Pharma Corporation:

    Involved in the development and marketing of inebilizumab.
    Celltrion Healthcare:

    Developed Truxima, a biosimilar to rituximab, which is sometimes used in NMO treatment.
    (Note: The list of the key market players can be updated with the latest market scenario and trends)

    Direct Purchase Report: https://www.regionalresearchreports.com/buy-now/neuromyelitis-optica-drug-market/HC-1358?opt=2950&utm_source=Free&utm_medium=Harsh+26+dec

    Global Neuromyelitis Optica Drug Market Growth, by Region and Country, 2018-2021, 2023-2030 (US$ Millions)
    Global Neuromyelitis Optica Drug Market Analysis, by Region and Country
    North America (US, Canada, Mexico)
    Europe (Germany, UK, France, Italy, Spain, Russia, Switzerland, Poland, Belgium, the Netherlands, Norway, Sweden, Czech Republic, Slovakia, Slovenia, Rest of Europe)
    Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Malaysia, Vietnam, Singapore, Australia & New Zealand, Rest of Asia Pacific)
    South America (Brazil, Argentina, Peru, Colombia, Rest of South America)
    The Middle East & Africa (UAE, Saudi Arabia, South Africa, Egypt, Qatar, Northern Africa, Rest of MEA)
    Neuromyelitis Optica Drug Market Research Methodology

    Similarly following is the list of a few paid secondary sources/databases,

    Pfizer
    Fresenius
    Teva
    Sandoz
    Intas
    Gyjtrs
    NANG KUANG
    Tianjin Kingyork
    Baxter
    CSL
    Grifols
    Octapharma
    CBOP
    Request For Report Discount: https://www.regionalresearchreports.com/request-for-special-pricing/neuromyelitis-optica-drug-market/HC-1358?utm_source=Free&utm_medium=Harsh+26+dec

    𝐍𝐞𝐮𝐫𝐨𝐦𝐲𝐞𝐥𝐢𝐭𝐢𝐬 𝐎𝐩𝐭𝐢𝐜𝐚 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐨 𝟑.𝟔𝟎% 𝐂𝐀𝐆𝐑 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝟐𝟎𝟑𝟎 According to Regional Research Reports," the Global Neuromyelitis Optica Drug Market is projected to reach USD 120 million by 2030 from USD 53 million in 2021, growing at a CAGR of 3.60% from 2022 to 2030. Regional Research Reports offers comprehensive insights into the global Neuromyelitis Optica Drug Market, facilitating an in-depth understanding of its dynamics. By conducting thorough research and employing robust data analysis techniques, this study aims to provide valuable insights into the current landscape of business, as well as the challenges and opportunities that shape the market under consideration. Considering the shifting dynamics of the environment, it is crucial to prioritize decision-making that is well-informed. The report provides individuals with the necessary knowledge and techniques to make informed and effective business decisions. Request Sample Copy of this Report: https://www.regionalresearchreports.com/request-sample/neuromyelitis-optica-drug-market/HC-1358?utm_source=Free&utm_medium=Harsh+26+dec Global Neuromyelitis Optica Drug Market Segmentation Key Market Segments: Immunosuppressants: Azathioprine Mycophenolate mofetil Rituximab Methotrexate Corticosteroids: Prednisone Methylprednisolone Plasma Exchange (PLEX): Used for acute attacks to remove antibodies from the blood. Monoclonal Antibodies: Eculizumab Other Therapies: Aquaporin-4 (AQP4) antibody-targeted therapies Inebilizumab Global Neuromyelitis Optica Drug Market Competitive: Key Players The report offers an exhaustive analysis of the key players operating in the Neuromyelitis Optica Drug Market( on a global scale. These competitors have implemented various strategies, including the introduction of new products, partnerships, growth, joint ventures, and agreements, among others, in order to expand their market presence and sustain their dominant positions in distinct regions. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023. The main players in the global market include – Genentech/Roche: Developed Satralizumab (Enspryng), a monoclonal antibody for NMO treatment. Viela Bio: Developed Inebilizumab (Uplizna), a B-cell-depleting antibody for the treatment of NMO. Alexion Pharmaceuticals: Developed Eculizumab (Soliris), a complement inhibitor used in the treatment of NMO. Horizon Therapeutics: Involved in the development of Ravulizumab, another complement inhibitor, for NMO treatment. Chugai Pharmaceutical (a member of the Roche Group): Collaborated on the development of Satralizumab. MedImmune/AstraZeneca: Involved in the development of Inebilizumab. Teva Pharmaceutical Industries: Manufacturer of glatiramer acetate (Copaxone), which may be used off-label in some cases. Mitsubishi Tanabe Pharma Corporation: Involved in the development and marketing of inebilizumab. Celltrion Healthcare: Developed Truxima, a biosimilar to rituximab, which is sometimes used in NMO treatment. (Note: The list of the key market players can be updated with the latest market scenario and trends) Direct Purchase Report: https://www.regionalresearchreports.com/buy-now/neuromyelitis-optica-drug-market/HC-1358?opt=2950&utm_source=Free&utm_medium=Harsh+26+dec Global Neuromyelitis Optica Drug Market Growth, by Region and Country, 2018-2021, 2023-2030 (US$ Millions) Global Neuromyelitis Optica Drug Market Analysis, by Region and Country North America (US, Canada, Mexico) Europe (Germany, UK, France, Italy, Spain, Russia, Switzerland, Poland, Belgium, the Netherlands, Norway, Sweden, Czech Republic, Slovakia, Slovenia, Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Malaysia, Vietnam, Singapore, Australia & New Zealand, Rest of Asia Pacific) South America (Brazil, Argentina, Peru, Colombia, Rest of South America) The Middle East & Africa (UAE, Saudi Arabia, South Africa, Egypt, Qatar, Northern Africa, Rest of MEA) Neuromyelitis Optica Drug Market Research Methodology Similarly following is the list of a few paid secondary sources/databases, Pfizer Fresenius Teva Sandoz Intas Gyjtrs NANG KUANG Tianjin Kingyork Baxter CSL Grifols Octapharma CBOP Request For Report Discount: https://www.regionalresearchreports.com/request-for-special-pricing/neuromyelitis-optica-drug-market/HC-1358?utm_source=Free&utm_medium=Harsh+26+dec
    Like
    1
    0 Comments 0 Shares 795 Views